Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia : Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers. / Norgaard, Caroline Holm; Friedrich, Sarah; Hansen, Charlotte Thim; Gerds, Thomas; Ballard, Clive; Moller, Daniel Vega; Knudsen, Lotte Bjerre; Kvist, Kajsa; Zinman, Bernard; Holm, Ellen; Torp-Pedersen, Christian; Morch, Lina Steinrud.
In: Alzheimers & dementia-Translational research & clinical interventions, Vol. 8, No. 1, 12268, 2022.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia
T2 - Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers
AU - Norgaard, Caroline Holm
AU - Friedrich, Sarah
AU - Hansen, Charlotte Thim
AU - Gerds, Thomas
AU - Ballard, Clive
AU - Moller, Daniel Vega
AU - Knudsen, Lotte Bjerre
AU - Kvist, Kajsa
AU - Zinman, Bernard
AU - Holm, Ellen
AU - Torp-Pedersen, Christian
AU - Morch, Lina Steinrud
PY - 2022
Y1 - 2022
N2 - IntroductionPeople with type 2 diabetes have increased risk of dementia. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are among the promising therapies for repurposing as a treatment for Alzheimer's disease; a key unanswered question is whether they reduce dementia incidence in people with type 2 diabetes. MethodsWe assessed exposure to GLP-1 RAs in patients with type 2 diabetes and subsequent diagnosis of dementia in two large data sources with long-term follow-up: pooled data from three randomized double-blind placebo-controlled cardiovascular outcome trials (15,820 patients) and a nationwide Danish registry-based cohort (120,054 patients). ResultsDementia rate was lower both in patients randomized to GLP-1 RAs versus placebo (hazard ratio [HR]: 0.47 (95% confidence interval [CI]: 0.25-0.86) and in the nationwide cohort (HR: 0.89; 95% CI: 0.86-0.93 with yearly increased exposure to GLP-1 RAs). DiscussionTreatment with GLP-1 RAs may provide a new opportunity to reduce the incidence of dementia in patients with type 2 diabetes.
AB - IntroductionPeople with type 2 diabetes have increased risk of dementia. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are among the promising therapies for repurposing as a treatment for Alzheimer's disease; a key unanswered question is whether they reduce dementia incidence in people with type 2 diabetes. MethodsWe assessed exposure to GLP-1 RAs in patients with type 2 diabetes and subsequent diagnosis of dementia in two large data sources with long-term follow-up: pooled data from three randomized double-blind placebo-controlled cardiovascular outcome trials (15,820 patients) and a nationwide Danish registry-based cohort (120,054 patients). ResultsDementia rate was lower both in patients randomized to GLP-1 RAs versus placebo (hazard ratio [HR]: 0.47 (95% confidence interval [CI]: 0.25-0.86) and in the nationwide cohort (HR: 0.89; 95% CI: 0.86-0.93 with yearly increased exposure to GLP-1 RAs). DiscussionTreatment with GLP-1 RAs may provide a new opportunity to reduce the incidence of dementia in patients with type 2 diabetes.
KW - dementia
KW - glucagon-like peptide-1 receptor agonists
KW - randomized controlled trial
KW - real-world evidence
KW - type 2 diabetes
KW - CARDIOVASCULAR OUTCOMES
KW - MOUSE MODEL
KW - LIRAGLUTIDE
KW - SEMAGLUTIDE
U2 - 10.1002/trc2.12268
DO - 10.1002/trc2.12268
M3 - Journal article
C2 - 35229024
VL - 8
JO - Alzheimers & dementia-Translational research & clinical interventions
JF - Alzheimers & dementia-Translational research & clinical interventions
IS - 1
M1 - 12268
ER -
ID: 333611482